GeneDx
Richard Lusk is a seasoned professional in the healthcare and analytics sectors, currently serving as Senior Vice President of Growth Finance and Senior Vice President of Growth Insight and Monetization Strategy at GeneDx since September 2023. Previously, Richard held multiple leadership roles at Invitae, overseeing financial planning and analytics from December 2021 to September 2023. Prior to that, Richard was the Sr. Director of Analytics & Insights at Blue Cross Blue Shield of Michigan, where key contributions included leading analytics for healthcare programs and establishing a Program Evaluation team. Earlier experience includes roles as an Engagement Manager at McKinsey & Company, focusing on healthcare strategy and implementation, as well as academic positions as a Postdoctoral Fellow at the University of Michigan and a Graduate Student Research Fellow at the University of California, Berkeley, where Richard developed advanced analytics tools for genomic data analysis. Richard holds a Ph.D. in Molecular & Cell Biology with a focus on Computational & Genomic Biology from the University of California, Berkeley, and a BA in Biology from the University of Chicago.
This person is not in any teams
This person is not in any offices
GeneDx
10 followers
GeneDx is focused on delivering personalized, actionable insights that improve health outcomes. We sit at the intersection of diagnostics and data science, pairing decades of genomic expertise with an unmatched ability to interpret clinical data at scale. Our exome and genome testing is among the best in the industry. We expect that it will be even more advanced in the future with the help of Centrellis®, our innovative health information platform. Powered by millions of medical records, Centrellis® integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data. As a result of our robust test menu, including our exome and genome testing, and the comprehensive insights generated by Centrellis®, we are developing a more complete understanding of complex disease than ever before. This translates to faster diagnosis, more effective treatment plans, and enhanced drug discovery. Our offerings help a whole spectrum of healthcare partners -- clinicians, researchers, health systems, pharmaceutical companies, and payors -- improve patient experiences and advance population health.